Identification |
Name: | Ergotaman-3',6',18-trione,2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'a)- |
Synonyms: | Ergocryptine,2-bromo- (8CI); 8H-Oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine,ergotaman-3',6',18-trione deriv.; Indolo[4,3-fg]quinoline,ergotaman-3',6',18-trione deriv.; (+)-Bromocriptine; 2-Bromo-a-ergocryptine; 2-Bromo-a-ergokryptine;2-Bromoergocriptine; 2-Bromoergocryptine; Bromergocryptine; Bromocriptin;Bromocriptine; Bromocryptine; Bromoergocryptine; Ergolactin; SAN 15-754; Sandoz15-754; a-Bromocryptine; a-Bromoergocryptine; a-Ergolactin |
CAS: | 25614-03-3 |
EINECS: | 247-128-5 |
Molecular Formula: | C32H40 Br N5 O5 |
Molecular Weight: | 654.68 |
InChI: | InChI=1/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 |
Molecular Structure: |
|
Properties |
Density: | 1.52 g/cm3 |
Refractive index: | 1.696 |
Appearance: | white crystalline powder |
Specification: |
Bromocriptine (25614-03-3) also can be called Parlodel ; Bromocriptin ; 2-Bromoergocryptine ; (5'a)-2-Bromo-12'-hydroxy-2'-(-1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione ; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)- and Bromocryptin .Its use has been associated with causing or worsening psychotic symptoms: its mechanism is in opposition of most antipsychotics, whose mechanisms generally block dopamine.
|
Report: |
EPA Genetic Toxicology Program.
|
Safety Data |
|
|